High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Clinical Oncology

• Publication date

  2010-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2009.24.4905PMID 20368570
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.

  2009cited by this paper
• International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

  2009cited by this paper
• International prognostic scoring system for Waldenstrom macroglobulinemia.

  2009cited by this paper
• Lenalidomide for the treatment of B-cell malignancies.

  2008cited by this paper
• Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide.

  2007cited by this paper
• Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.

  2007cited by this paper
• Autologous stem cell transplantation as part of first-line treatment of Waldenström's macroglobulinemia.

  2007cited by this paper
• Hematopoietic Stem Cell Transplantation (HSCT) in Waldenström Macroglobulinemia (Wm), Update of the French Experience in 54 Cases.

  2007cited by this paper
• Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia.

  2006cited by this paper
• Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia.

  2006cited by this paper
• Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia.

  2006cited by this paper
• Diagnosis and management of Waldenstrom's macroglobulinemia.

  2005cited by this paper
• Multicenter Phase 2 Trial of Rituximab for Waldenström Macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98)

  2004cited by this paper
• Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

  2003cited by this paper
• Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases

  2001cited by this paper
• Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling

  2001cited by this paper
• patients with the description of a new scoring system and its validation on 253 other patients.

  2000cited by this paper
• WaldenstroÈm's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil

  2000cited by this paper
• Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

  1999cited by this paper
• Waldenstrom's macroglobulinemia.

  1994cited by this paper
• Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases.

  1993cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Report of Consensus Panel 3 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with high-risk disease.

  2025cites this paper
• Current and emerging treatment perspectives for adults with Waldenström macroglobulinemia

  2025cites this paper
• Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 2- Focus on Therapy

  2025cites this paper
• Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.

  2024cites this paper
• How to manage waldenström's macroglobulinemia in 2024.

  2024cites this paper
• Autologous and Allogeneic Stem‐Cell Transplantation for Transformed Waldenström Macroglobulinemia

  2024cites this paper
• BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia

  2023influential citation
• Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects

  2023cites this paper
• Current approach to Waldenström macroglobulinemia.

  2023cites this paper
• Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients.

  2023cites this paper
• The Management of Relapsed or Refractory Waldenström's Macroglobulinemia.

  2023cites this paper
• Treatment of relapsed and refractory Waldenstrom Macroglobulinemia

  2022cites this paper
• Diagnosis and management of Waldenström macroglobulinaemia—A British Society for Haematology guideline

  2022cites this paper
• Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement

  2022cites this paper
• Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond

  2022cites this paper
• Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022

  2022cites this paper
• Managing Waldenström’s macroglobulinemia with BTK inhibitors

  2022cites this paper
• First-Line Treatment of Waldenström’s Macroglobulinaemia: Considerations Based on the Dutch National Guideline

  2022cites this paper
• Bruton Tyrosine Kinase Inhibitors in Waldenstrom Macroglobulinemia: Unprecedented Clinical Activity and Promising Future Directions.

  2021cites this paper
• Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions.

  2021cites this paper
• Post‐relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation

  2021cites this paper
• Managing complications secondary to Waldenström’s macroglobulinemia

  2021cites this paper
• Outcome of stem cell transplantation for Waldenström’s macroglobulinemia: analysis of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group

  2020cites this paper
• Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies

  2020cites this paper
• Waldenström Macroglobulinemia - 2020 Update on Management and Future Directions.

  2020cites this paper
• Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia

  2020cites this paper
• Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia.

  2020cites this paper
• Rare manifestation of Waldenström macroglobulinemia with acute kidney injury secondary to cast nephropathy in a young woman

  2020cites this paper
• Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenström Macroglobulinemia: A Systematic Review and Meta-analysis.

  2020cites this paper
• Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management

  2020cites this paper
• Chimeric antigen receptor T cells for treatment of transformed Waldenström macroglobulinemia

  2020cites this paper
• Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.

  2020cites this paper
• An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia

  2020cites this paper
• IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features

  2019cites this paper
• How I treat Waldenström's Macroglobulinemia.

  2019cites this paper
• JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-3. Lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia (LPL/WM)

  2019cites this paper
• Current Therapeutic Options in Waldenström Macroglobulinemia

  2019cites this paper
• Outcomes of autologous stem cell transplantation in Waldenström’s macroglobulinemia

  2019cites this paper
• Current Therapeutic Options in Waldenström Macroglobulinemia Management of peripheral neuropathy in Waldenström macroglobulinemia

  2019cites this paper
• Updates in prognostication and treatment of Waldenström's macroglobulinemia.

  2019cites this paper
• High‐dose therapy with autologous stem cells transplantation in Bing‐Neel syndrome: A retrospective analysis of 14 cases

  2019cites this paper
• Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019

  2019cites this paper
• Guidelines of the Belgian Hematology Society on the use of stem cell transplantation in lymphoproliferative diseases

  2019cites this paper
• Novel Therapeutics in the Management of Waldenström Macroglobulinemia

  2019cites this paper
• How we manage patients with Waldenström macroglobulinaemia

  2018cites this paper
• Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2018cites this paper
• Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia-Reply.

  2018cites this paper
• Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management

  2018cites this paper
• High-Dose Therapy and Hematopoietic Stem Cell Transplantation in Waldenström Macroglobulinemia.

  2018cites this paper
• Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia

  2018cites this paper
• Diagnostic and Therapeutic Challenges.

  2018cites this paper
• A safety profile of medications used to treat Waldenström’s macroglobulinemia

  2018cites this paper
• Retrospective analysis of prognostic factors for Waldenstrӧm macroglobulinemia: a multicenter cooperative study in Japan

  2017cites this paper
• High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation

  2017cites this paper
• Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016

  2017cites this paper
• Toward personalized treatment in Waldenström macroglobulinemia.

  2017cites this paper
• What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy.

  2017cites this paper
• Disease control should be the goal of therapy for WM patients.

  2017cites this paper
• Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21st century

  2017cites this paper
• Diagnostic and therapeutic challenges.

  2017cites this paper
• [Waldenström's macroglobulinemia and its individualized therapy options].

  2017cites this paper
• Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group

  2017cites this paper
• Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management

  2017cites this paper
• Multifactorial Elements Affecting Bone Mineral Status and Growth in Children with Thalassemia Major

  2017cites this paper
• A Waldenström-macroglobulinaemia és betegségre szabott kezelése

  2017cites this paper
• Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment.

  2016cites this paper
• The role of autologous and allogeneic stem cell transplantation in the management of indolent B-cell lymphoma.

  2016cites this paper
• Reappraising the timing of transplant for indolent non-Hodgkin lymphomas

  2016cites this paper
• Are New Treatment Options Shifting How and When We Treat Waldenström Macroglobulinemia

  2016cites this paper
• The role of stem cell transplantation in Waldenstrom's macroglobulinemia.

  2016cites this paper
• Waldenström macroglobulinemia: biology, genetics, and therapy

  2016influential citation
• Waldenström’s macroglobulinaemia : Belgian Hematology Society guidelines

  2015cites this paper
• Waldenstrom macroglobulinemia: prognosis and management

  2015cites this paper
• Biology, prognosis, and therapy of Waldenström Macroglobulinemia.

  2015cites this paper
• Waldenström macroglobulinemia.

  2015cites this paper
• Role of transplantation in lymphoplasmacytic lymphoma

  2015cites this paper
• Waldenström macroglobulinemia: What a hematologist needs to know.

  2015cites this paper
• [Waldenström's macroglobulinemia].

  2015cites this paper
• Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective

  2015cites this paper
• How I treat Waldenstr¨ om macroglobulinemia

  2015cites this paper
• Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015

  2015cites this paper
• Why Waldenström macroglobulinemia is not just another indolent lymphoma

  2014cites this paper
• macroglobulinemia (WM) and related disorders: IWWM-7 consensus Treatment recommendations for patients with Waldenström

  2014cites this paper
• Waldenström macroglobulinemia at 70

  2014cites this paper
• Waldenstrom’s Macroglobulinemia

  2014cites this paper
• Current and future therapeutic approach for Waldenström's macroglobulinemia.

  2014cites this paper
• Guidelines on the diagnosis and management of Waldenström macroglobulinaemia

  2014cites this paper
• Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia

  2014cites this paper
• Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.

  2014influential citation
• T-cell lymphoma with POEMS syndrome

  2014cites this paper
• Waldenström macroglobulinemia.

  2014cites this paper
• Maladie de Waldenström ou macroglobulinémie

  2014cites this paper
• BEAM-conditioned autologous SCT improves the quality of response in Waldenström’s macroglobulinaemia and lymphoplasmacytic lymphoma: a single centre’s 10-year experience

  2014cites this paper
• Guideline for diagnosis and treatment of Waldenström's macroglobulinaemia.

  2013cites this paper
• Waldenström macroglobulinemia: my way

  2013cites this paper
• Patterns of survival in lymphoplasmacytic lymphoma/waldenström macroglobulinemia: A population‐based study of 1,555 patients diagnosed in Sweden from 1980 to 2005

  2013cites this paper
• How to manage Waldenstrom's macroglobulinemia

  2013cites this paper
• Waldenström macroglobulinaemia: the key questions

  2013cites this paper
• Waldenström's macroglobulinemia: treatment approaches for newly diagnosed and relapsed disease.

  2013cites this paper
• Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant?

  2013cites this paper